Publication Name	World Journal of Immunology
Manuscript ID	12305
Country	United States

Received	2014-07-01 09:34
Peer-Review Started	2014-07-01 13:55
To Make the First Decision	2014-09-28 14:00
Return for Revision	2014-09-29 17:39
Revised	2014-10-23 22:35
Second Decision	2014-11-12 13:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-11-19 11:09
Articles in Press	2014-11-19 11:10
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-03-26 19:08
Publish the Manuscript Online	2015-03-31 10:28

ISSN	2219-2824 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Review
Article Title	Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches
Manuscript Source	Invited Manuscript
All Author List	Mira A Patel, Jennifer E Kim, Jacob Ruzevick and Michael Lim
Funding Agency and Grant Number
Corresponding Author	Michael Lim, MD, Associate Professor of Neurosurgery and Oncology, Department of Neurosurgery, the Johns Hopkins University School of Medicine, 600 N. Wolfe St., Phipps Building Rm 123, Baltimore, MD 21287, United States. mlim3@jhmi.edu
Key Words	Programmed death-1; Cytotoxic T lymphocyte associated antigen-4; Ipilimumab; Nivolumab; Immune checkpoint
Core Tip	Aggressive cancer growth is often characterized by tumor expression of molecules that co-opt effective immune responses through immune checkpoints. Clinical blockade of checkpoints programmed death-1 and cytotoxic T lymphocyte associated antigen-4 and has spurred the discovery of a number of immune checkpoints that may be inhibited in anticancer therapy. The clinical successes of checkpoint blockade have led to increasing interest in combining treatment modalities. Combination checkpoint blockade with chemoradiation has shown synergistic effects, and checkpoint blockade with bacterial vaccine vectors have produced increased immune responses in pre-clinical models. The future of immune checkpoint blockade may be as a powerful adjuvant alongside the current standard of care.
Publish Date	2015-03-31 10:28
Citation	Patel MA, Kim JE, Ruzevick J, Lim M. Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World J Immunol 2015; 5(1): 1-15
URL	http://www.wjgnet.com/2219-2824/full/v5/i1/1.htm
DOI	http://dx.doi.org/10.5411/wji.v5.i1.1

Full Article (PDF)	WJI-5-1.pdf
Full Article (Word)	WJI-5-1.doc
Manuscript File	12305-Review.docx
Answering Reviewers	12305-Answering reviewers.pdf
Copyright License Agreement	12305-Copyright assignment.pdf
Peer-review Report	12305-Peer review(s).pdf
Scientific Misconduct Check	12305-CrossCheck.jpg
Scientific Editor Work List	12305-Scientific editor work list.pdf